Sanofi President, Global Operations, to retire

 
12/18/2012 09:17:15 AM

[TOD Wire]

Published Date: December 18, 2012 09:16:00 AM EST

PR Newswire/Les Echos/

PRESS RELEASE

Sanofi President, Global Operations, to retire

Paris, France - December 18, 2012 - Sanofi (EURONEXT : SAN and NYSE : SNY)
announced today that Hanspeter Spek, President, Global Operations, will retire
from his current role in mid-2013. A succession plan will be announced in due
course.

Christopher A. Viehbacher, Chief Executive Officer of Sanofi said: "During his
many years with Sanofi, Hanspeter has made an exceptional contribution to the
success of the Group and has helped bring Sanofi to the fore front of the
industry. He has been a key member of the Executive Committee which has
transformed Sanofi as a healthcare leader. His early recognition of growing
opportunities in the emerging markets has contributed to the building of
Sanofi's leading position there. With the Group now having an outlook of long
term sustainable growth, I would like to sincerely thank Hanspeter for his
leadership, commitment and energy and wish him the very best for the future".

Hanspeter Spek joined the Group in 1985 as Marketing Director with Sanofi
Pharma GmbH Germany. Throughout his tenure, he worked his way right up through
the Group and was appointed to his current position as President, Global
Operations in November 2009. He has been instrumental in the evolution of the
Group, contributing to the significant success of flagship products such as
Plavix(r), Lantus(r) and Taxotere(r), and has always been an inspirational
leader and a key player in the various partnerships Sanofi has entered into and
the integrations of Synthelabo in 1999, Aventis in 2004 and more recently
Chattem and Merial. Hanspeter Spek will retain his role as Chairman of the
Supervisory Board of Sanofi GmbH Germany during a transitional period.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).

Contacts:
Media Relations Investor Relations
Jean-Marc Podvin Sébastien Martel
Tel.: + (33) 1 53 77 46 46 Tel.: + (33) 1 53 77 45 45
mr@sanofi.com ir@sanofi.com

The content and accuracy of news releases published on this site and/or
distributed by PR Newswire or its partners are the sole responsibility of the
originating company or organisation. Whilst every effort is made to ensure the
accuracy of our services, such releases are not actively monitored or reviewed
by PR Newswire or its partners and under no circumstances shall PR Newswire or
its partners be liable for any loss or damage resulting from the use of such
information. All information should be checked prior to publication.